



Controlled Trial of Tadalafil in Raynaud Phenomenon (RP) secondary to Systemic Sclerosis (SSc)

Elena Schiopu M.D.¹, Vivien M. Hsu M.D.², Ann J. Impens Ph.D.¹, Jennifer A. Guerriere-Rothman M.D.², Deborah A. McCloskey B.S.N.², Julianne E. Wilson R.N.², James R. Seibold, M.D.¹

¹University of Michigan Scleroderma Program, Ann Arbor, Michigan, ²UMDNJ Scleroderma Program, New Brunswick, New Jersey

Abstract

Objective :
Type V cGMP phosphodiesterase inhibitors (PDE-5) are reported as useful in the treatment of RP and for the ischemically threatened digit in SSc. Controlled trials are lacking.

Methods:
39 patients with SSc and RP were recruited for a randomized, double-blinded, placebo-controlled, cross-over study of tadalafil at 20 mg daily. Quality of female sexual function was a co-primary outcome hence all patients were women. The mean age was 52.9 ± 10.6 years. Of the 39 subjects, 29 (74.4%) had limited and 10 (25.6%) had diffuse scleroderma. The mean duration of RP was 11.8 ± 10 years. Eligible subjects recorded daily diaries of RP episodes and Raynaud Condition Score (RCS) for 2 weeks. The average number of RP attacks per week was 20.7 ± 12.3. Subjects that had at least 6 RP attacks per week were randomized to 20 mg tadalafil or placebo daily for 4 weeks followed by a 2 week wash-out and then 4 weeks of crossover therapy. The safety and tolerability were assessed by monitoring adverse effects (AE), vital signs, clinical laboratories and physical examination findings. Efficacy was assessed utilizing a daily paper diary including RCS. Duration and frequency of RP attacks were secondary efficacy outcomes.

Results:
There were no severe AEs. Common AEs included headache (32.5%), myalgia (22.5%), fluid retention (10%), vasomotor changes (7.5%), fatigue (5%), sleep disturbances (5%) and palpitations (5%). 5 subjects reported no AEs. Measures of efficacy are reported as mean change from baseline. All differences were not significant: RCS (t (38) = -0.36, p = 0.71), RP Frequency (t (38) = -0.08, p = 0.93) and RP Duration (t (38) = -1.15, p = 0.25). There were too few digital ulcers to permit analysis. Several validated questionnaires of quality of female sexual function showed no effects (data not presented).

Conclusions:
Tadalafil is a long acting PDE-5 inhibitor amenable to once daily dosing. It appears to be well tolerated in women with SSc and RP. The present data do not support its use as a therapy for RP secondary to SSc although studies in pulmonary hypertension-SSc are in progress. Placebo effect remains a prominent issue in RP clinical trial design.


Background and Rationale

- Raynaud phenomenon is present in 95% of patients with SSc
- Severity, frequency and duration of Raynaud attacks have great impact on activities of daily living and may cause digital ulceration
- Vasodilators have been used to treat RP with variable success and side effects
- There are currently no approved therapies for RP
- Type V cGMP selective inhibitors are effective microvascular and macrovascular dilators by prolonging the bioavailability of cGMP — a key downstream mediator of NO
- PDE-5 inhibitors have been reported as useful in the treatment of RP and ischemically threatened digit in SSc
- Randomized controlled studies are lacking
- This present study was designed to assess safety and efficacy of Tadalafil in patients with RP secondary to SSc

Patients and Methods

- 39 female patients with a mean age of 52.9 ± 10.6 years
- 29 (74.4%) had limited and 10 (25.6%) had diffuse scleroderma
- The mean duration of RP was 11.8 ± 10 years
- The average number of RP attacks per week was 20.7 ± 12.3

This study is a randomized, double-blinded, placebo-controlled, cross-over study of tadalafil at 20 mg daily.



- Subjects that had at least 6 RP attacks per week were randomized to 20 mg tadalafil or placebo
- Primary objective was to assess safety and tolerability of Tadalafil (AEs, vital signs, labs)
- Efficacy was assessed utilizing a daily paper diary including RCS, with duration and frequency of RP attacks being secondary outcomes
- Quality of female sexual function was a co-primary outcome; we used sexual activity diaries and a sexual function questionnaire FSFI (Female Sexual Function Index)

Results

Safety and Tolerability

- No severe AEs were noted
- Common AEs included:

headache	32.5%
myalgia	22.5%
fluid retention	10%
vasomotor changes	7.5%
fatigue	5%
sleep disturbances	5%
palpitations	5%

Efficacy

Measures of efficacy are reported as mean change from baseline and revealed:

	RCS (cm)	RP Frequency (per day)	RP Duration (min)
Baseline	3.76	2.93	53.42
Tadalafil	-1.33	-0.85	-12.81
Placebo	-1.23	-0.83	-6.42

All differences were not significant:

- RCS (t (38) = -0.36, p = 0.71)
- RP Frequency (t (38) = -0.08, p = 0.93)
- RP Duration (t (38) = -1.15, p = 0.25)

There were too few digital ulcers to permit analysis. Several validated questionnaires of quality of female sexual function showed no effects.

Conclusions

- Tadalafil appears to be well tolerated in women with RP and SSc
- Long half life makes it amenable to once a day dosing
- In the absence of a clinical effect on RP, our data does not support the use of Tadalafil as a therapy for RP secondary to SSc
- Based on the sample size, our study had 60% power for a 20% treatment effect
- Placebo effect remains a prominent issue in RP clinical trial design

References

1. Merkel PA, Herlyn K, Martin RW, Anderson JJ, Mayes MD, Bell P, Korn JH, Simms RW, Csuka ME, Medsger TA Jr, Rothfield NF, Ellman MH, Collier DH, Weinstein A, Furst DE, Jimenez SA, White B, Seibold JR, Wigley FM; Scleroderma Clinical Trials Consortium. Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon. *Arthritis Rheum.* 2002 Sep;46(9):2410-20
2. Caglayan E, Huntgeburth M, Karasch T, Weihrauch J, Hunzelmann N, Krieg T, Erdmann E, Rosenkranz S. Phosphodiesterase type 5 inhibition is a novel therapeutic option in Raynaud disease. *Arch Intern Med.* 2006 Jan 23;166(2):231-3

Acknowledgement

The study was an Investigator IND supported in part by a grant from Lilly ICOS LLC., Indianapolis, IN